Leanne Clevenger, MD
Retina Specialist · Lexington, KYNPI 1245735414
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,100 of the $17,399 with a category attached, or 63.8%. 11 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 56.9% of the total. 2025 is the largest year on record at $11,443, more than ten times the $100 reported in 2019.
Across 49 payments — averaging $355.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$10K
- Harrow Eye, LLC$3K
- Ocular Therapeutix, Inc.$2K
- Regeneron$1K
- Alimera Sciences, Inc.$613
- Apellis Pharmaceuticals, Inc.$348
- plus $658 from 5 others
Across 2 payments — averaging $4603.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$9K
What the payments were for
- Consulting fees$11,10064%
- Speaking & faculty fees$3502%
- Grants$1,3007%
- Travel & lodging$2,16312%
- Food & beverage$2,38614%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 29 | $9,908 |
| Harrow Eye, LLC | 2 | $2,931 |
| Ocular Therapeutix, Inc. | 1 | $1,500 |
| Regeneron | 3 | $1,442 |
| Alimera Sciences, Inc. | 3 | $613 |
| Apellis Pharmaceuticals, Inc. | 3 | $348 |
| Alcon | 3 | $339 |
| AbbVie | 1 | $100 |
| Genentech USA, Inc. | 1 | $85 |
| Eyepoint US, Inc. | 2 | $68 |
| Kedrion Biopharma, Inc. | 1 | $66 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRIESENCE$2,931
- STELLARIS$997
- OPHTHALMIC INSTRUMENTS$997
- STELLARIS ELITE$800
- Iluvien$613
- SURGICAL MISC$400
- NGENUITY$146
- EYLEA$142
- Syfovre$120
- Constellation$110
How this compares
$17,399 in reported general payments places this provider in the 75th percentile of 22 retina specialist providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 54 | $2,141 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $414 |
| Atropine Sulfate | 12 | $331 |
| Ciprofloxacin Hcl | 11 | $149 |
| Ofloxacin | 13 | $136 |
| Latanoprost | 26 | $95 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Lexington
- John KitchensLexington$1.1M
- Blake IsernhagenLexington$183K
- Miguel BusquetsLexington$92K
- Romulo AlbuquerqueLexington$20K
- Todd PurkissLexington$11K
- Belinda ShirkeyLexington$11K
- Ricky IsernhagenLexington$5K
- Aaron RiccaLexington$5K
- William WoodLexington$5K
- Osama SabbaghLexington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.